MedPath

Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome

Conditions
Dravet Syndrome
Registration Number
NCT01983722
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Brief Summary

Expanded access to Stiripentol for patients with Dravet Syndrome.

Detailed Description

This is a treatment plan, and therefore patients will be monitored according to clinical standard of care.

Recruitment & Eligibility

Status
APPROVED_FOR_MARKETING
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • 6 months and older
  • Diagnosis of Dravet Syndrome with intractable seizures
Exclusion Criteria
  • Hypersensitivity to the active substance or to any of the excipients
  • Past history of psychoses in the form of episodes of delirium
  • Impaired hepatic and/or renal function, defined as creatinine >2 and/or transaminase >4xULN

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath